PMID- 35613850
OWN - NLM
STAT- MEDLINE
DCOM- 20220527
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0393 (Print)
IS  - 1753-0407 (Linking)
VI  - 14
IP  - 5
DP  - 2022 May
TI  - Follow-up frequency and clinical outcomes in patients with type 2 diabetes: A 
      prospective analysis based on multicenter real-world data.
PG  - 306-314
LID - 10.1111/1753-0407.13271 [doi]
AB  - BACKGROUND: To determine whether the follow-up frequency for type 2 diabetes 
      mellitus (T2DM) patients in the National Metabolic Management Centers (MMCs) 
      leads to different clinical outcomes. METHODS: A total of 19 908 T2DM patients 
      with at least 6 months of facility-based follow-up were recruited in MMCs between 
      June 2017 and April 2021 and divided into lower-frequency and higher-frequency 
      follow-up (LFF and HFF) groups according to the median follow-up frequency of 2.0 
      (interquartile range 1.2) times per year. Metabolic parameters at baseline and at 
      the last follow-up visit were analyzed. Multivariable linear regression models 
      were performed to assess the relationship between follow-up frequency and 
      between-group percentage changes, adjusting for the major covariables. Additional 
      stratified analyses were conducted to evaluate the metabolic outcomes in the 
      subgroups. RESULTS: The characteristics of the participants in the LFF and HFF 
      groups were significantly different at baseline. Participants had significant 
      improvements in multiple metabolic parameters after follow-up. Patients with HFF 
      showed significantly greater decrease in percentage changes of fasting blood 
      glucose (-4.95% +/- 37.96% vs -2.21% +/- 43.08%, P < .0001) and glycosylated 
      hemoglobin (HbA1c) (-12.14% +/- 19.78% vs -9.67% +/- 20.29%, P < .0001) after 
      adjustments compared to those with LFF. Furthermore, stratification analyses 
      showed that significant between-group percentage changes of HbA1c were observed 
      in those with younger age (<55 years) and higher HbA1c (>9%) at baseline (P for 
      interaction <.001). CONCLUSIONS: HFF is associated with better metabolic 
      outcomes. Participants, especially with younger age or worse HbA1c at baseline in 
      the HFF group achieved better glycemic control than those in the LFF group.
CI  - (c) 2022 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai 
      Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
FAU - Zhao, Qiubo
AU  - Zhao Q
AD  - Department of Endocrinology and Metabolism, Hebi Coal (group) Ltd, General 
      Hospital, Hebi, China.
FAU - Li, Hongwei
AU  - Li H
AD  - Department of Endocrinology and Metabolism, Hebi Coal (group) Ltd, General 
      Hospital, Hebi, China.
FAU - Ni, Qicheng
AU  - Ni Q
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Dai, Yuancheng
AU  - Dai Y
AD  - Department of Internal Medicine of Traditional Chinese Medicine, Sheyang Diabetes 
      Hospital, Yancheng, China.
FAU - Zheng, Qidong
AU  - Zheng Q
AD  - Department of Internal Medicine, The Second People's Hospital of Yuhuan, Yuhuan, 
      China.
FAU - Wang, Yufan
AU  - Wang Y
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Ke, Tingyu
AU  - Ke T
AD  - Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Endocrinology, Ningbo First Hospital, China.
FAU - Zhao, Dong
AU  - Zhao D
AUID- ORCID: 0000-0002-9847-5439
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
FAU - Dong, Qijuan
AU  - Dong Q
AD  - Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou 
      Affiliated Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Ji, Bangqun
AU  - Ji B
AD  - Department of Endocrinology, Xingyi People's Hospital, Xingyi, China.
FAU - Shi, Juan
AU  - Shi J
AUID- ORCID: 0000-0003-2652-8084
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Peng, Ying
AU  - Peng Y
AUID- ORCID: 0000-0003-1069-7000
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Zhang, Yifei
AU  - Zhang Y
AUID- ORCID: 0000-0003-0272-0602
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Xu, Fengmei
AU  - Xu F
AD  - Department of Endocrinology and Metabolism, Hebi Coal (group) Ltd, General 
      Hospital, Hebi, China.
FAU - Wang, Weiqing
AU  - Wang W
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
LA  - eng
GR  - No. Z155080000004/Capacity building for multidisciplinary cooperation in 
      diagnosis and treatment of major metabolic diseases/
GR  - 2019-XZ-42/Chinese Academy of Engineering/
GR  - 2016YFC0901200/National Key Research and Development Program of China/
GR  - 2018YFC1311800/National Key Research and Development Program of China/
GR  - 82100835/National Natural Science Foundation of China/
GR  - 2019LJ07/Program for Shanghai Outstanding Medical Academic Leader/
GR  - DMRFP_II_01/Shanghai Medical and Health Development Foundation/
GR  - 21YF1426900/Shanghai Sailing Program/
PT  - Journal Article
PT  - Multicenter Study
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/metabolism
MH  - Glycemic Control
MH  - Humans
MH  - Middle Aged
PMC - PMC9366569
OTO - NOTNLM
OT  - 2型糖尿病
OT  - cost-effectiveness
OT  - follow-up frequency
OT  - glycemic control
OT  - type 2 diabetes mellitus
OT  - 成本效益
OT  - 血糖控制
OT  - 随访频率
EDAT- 2022/05/26 06:00
MHDA- 2022/05/28 06:00
PMCR- 2022/05/25
CRDT- 2022/05/25 21:12
PHST- 2022/04/12 00:00 [revised]
PHST- 2021/12/05 00:00 [received]
PHST- 2022/04/21 00:00 [accepted]
PHST- 2022/05/25 21:12 [entrez]
PHST- 2022/05/26 06:00 [pubmed]
PHST- 2022/05/28 06:00 [medline]
PHST- 2022/05/25 00:00 [pmc-release]
AID - JDB13271 [pii]
AID - 10.1111/1753-0407.13271 [doi]
PST - ppublish
SO  - J Diabetes. 2022 May;14(5):306-314. doi: 10.1111/1753-0407.13271.